IPO News | Bangshun Pharmaceutical's Hong Kong Stock IPO Prospectus Expires

Zhitongcaijing · 3d ago

The Zhitong Finance App learned that the Hong Kong stock prospectus submitted by Hangzhou Bangshun Pharmaceutical Co., Ltd. (Bangshun Pharmaceutical for short) on January 22, 2026 expired for 6 months and expired on July 22, 2026. CITIC Construction Investment International is its sole sponsor.

image.png

According to the prospectus, Bangshun Pharmaceutical is a biotechnology company focusing on the field of cancer and autoimmune diseases. The company has established a pipeline covering a new drug application (NDA) stage candidate (bezexitinib), a registered clinical-stage drug candidate (CX1440), and five pre-clinical stage drug candidates (CX03, CX12, CX13, CX15 and CX16).